http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210081353-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_10a77948035833454698753b762d551a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2019-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_63201f961f7f63e1a861755dfd917ede http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_207e54fe6262b0ea29af722f856771ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a29f9610242f09c41efcacd366bd9c49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15abfbaceca85b41d0d0f93b2bd5fb9e |
| publicationDate | 2021-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210081353-A |
| titleOfInvention | Heterocyclic kinase inhibitors and uses thereof |
| abstract | The present invention relates to kinase inhibitors, in particular inhibitors of protein kinases, for example protein-tyrosine kinases LCK, ABL, SRC, KIT, SIK-family and/or mutants thereof. Although structurally similar to dasatinib, the kinase inhibitors of the present invention may exhibit one or more specific properties that distinguish them from dasatinib. The invention also relates to pharmaceutical compositions comprising one or more kinase inhibitors. A kinase inhibitor or pharmaceutical composition of the present invention may be used to treat a disorder or condition, such as a proliferative disorder, such as leukemia or a solid tumor. The kinase inhibitor or pharmaceutical composition may be used in a therapeutic regimen corresponding to, similar to or distinct from that used with dasatinib for the corresponding disorder, in particular one or more additional therapeutic agents, e.g., immuno- It may be used in combination treatment regimens with checkpoint inhibitors. |
| priorityDate | 2018-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1140.